Clinical Trials Logo

Clinical Trial Summary

This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxicity compared with the historically reported rate for non-adaptive radiation therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 assessment tool will be utilized.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05700227
Study type Interventional
Source Varian, a Siemens Healthineers Company
Contact Steve Kohlmyer, MS
Phone 12062760076
Email steve.kohlmyer@varian.com
Status Recruiting
Phase N/A
Start date February 2, 2023
Completion date February 1, 2027